Assignment history

Inventors

• Mohammed N. Islam (Employer: Omni Medsci Inc at the time of filing, as he is listed as an inventor and current assignee of other patents filed by Omni Medsci Inc.)

Original assignee

The original assignee on the issued patent US9055868B2 is Omni Medsci Inc. Based on available information, Omni Medsci Inc. appears to be a technology company focused on developing near-infrared and mid-infrared broadband lasers for various applications, including medical devices. While the patent itself describes a "system and method for voice control of medical devices" and related diagnostic systems, it is unclear from the provided text whether Omni Medsci Inc. directly ships a product embodying the claims of this specific patent. Other patents assigned to Omni Medsci Inc. describe wearable devices for non-invasive blood measurements and remote sensing systems. The current status of Omni Medsci Inc. is operating, as they are listed as the current assignee of the patent.

Assignment timeline

• 2022-02-00 (executed) / recorded 2022-10-28 — Reel 059952/1000
  • Conveyance: Assignment
  • Assignor: OMNI MEDSCI, INC.
  • Assignee: OMNI CONTINUUM, LLC
  • Correspondent: Robert R. Deleault, ESQ., 1109 Springbrook Dr, SE, Grand Rapids, MI 49506. This correspondent later recurs in this chain.
  • Context: Internal reorg/transfer to affiliated entity.
• 2022-06-01 (executed) / recorded 2023-03-28 — Reel 061614/0001
  • Conveyance: Assignment
  • Assignor: OMNI CONTINUUM, LLC
  • Assignee: CHEETAH OMNI LLC
  • Correspondent: Robert R. Deleault, ESQ., 1109 Springbrook Dr, SE, Grand Rapids, MI 49506. This correspondent recurs in this chain.
  • Context: Internal reorg/transfer to affiliated entity.
• 2023-10-00 (executed) / recorded 2024-10-16 — Reel 065749/0569
  • Conveyance: Assignment
  • Assignor: CHEETAH OMNI LLC
  • Assignee: OMNI MEDSCI, INC.
  • Correspondent: Not specified in available data.
  • Context: Reassignment, likely an internal restructuring or consolidation.

Timeline diagram

timeline
    title Ownership of US 9055868
    2014 : Application filed
    2015 : Patent Issued
    2022 : Assigned to Omni Continuum LLC
    2023 : Assigned to Cheetah Omni LLC
    2024 : Reassigned to Omni Medsci Inc

NPE / troll-pattern signals

1. Shell-entity transfer — Present.

   • 2022-02-00 (executed) / recorded 2022-10-28 — Reel 059952/1000: Omni Medsci Inc. transferred 11 patents, including US9055868, to Omni Continuum LLC. Omni Continuum LLC was formed in Michigan in November 2013 and does not appear to have its own product line related to the patent's subject matter. ContinuumCloud, LLC (which shares a similar name to Omni Continuum, LLC) focuses on cloud-based solutions for behavioral health and human services, which is unrelated to medical device voice control.
   • 2022-06-01 (executed) / recorded 2023-03-28 — Reel 061614/0001: Omni Continuum LLC transferred the patent to Cheetah Omni LLC. Cheetah Omni LLC was formed in Texas in August 2002 and its listed director is Mohammed N. Islam (the inventor). Cheetah Omni appears to be primarily involved in receiving patents via transfer from Islam or his controlled entities, and there is no clear evidence of product development or sales related to the patent. Other entities named "Cheetah" produce unrelated products such as financial software and frame machines.

2. Known asserter in the chain — Present.

   • Omni Medsci Inc. has filed litigation alleging infringement of US9055868 and other patents against companies like Fossil, OnePlus, Oura Health, and Samsung in the Eastern District of Texas. This type of litigation pattern, especially in a common NPE venue like the Eastern District of Texas, is characteristic of a patent assertion entity (PAE) or NPE.

3. Repeat correspondent across the chain — Present.

   • Robert R. Deleault, ESQ., of 1109 Springbrook Dr, SE, Grand Rapids, MI 49506, is listed as the correspondent for both the 2022-02-00 / 2022-10-28 (Reel 059952/1000) and 2022-06-01 / 2023-03-28 (Reel 061614/0001) assignments. The consistent use of the same attorney for multiple transfers within the chain, particularly for entities like Omni Continuum and Cheetah Omni which appear to be related to the inventor and primarily engaged in patent transfers, is a strong indicator of an NPE pattern.

4. Cascading transfers — Present.

   • The patent was transferred from Omni Medsci Inc. to Omni Continuum LLC in February 2022 and then to Cheetah Omni LLC in June 2022, with both transfers occurring within a four-month period. This rapid succession of transfers between related entities suggests a cascading transfer pattern often seen with NPEs.

5. Pre-litigation transfer — Present.

   • The patent was involved in litigation filed by Omni Medsci Inc. against Fossil, OnePlus, Oura Health, and Samsung in January 2025. The transfers to Omni Continuum LLC (February 2022) and Cheetah Omni LLC (June 2022) and the subsequent reassignment back to Omni Medsci Inc. (October 2023) all occurred prior to this litigation. This timing suggests that the patent ownership was being organized to enable assertion, with the final transfer back to Omni Medsci Inc. occurring approximately 15 months before the litigation filing.

6. Bankruptcy fire-sale — Not present. There is no indication of bankruptcy proceedings for Omni Medsci Inc. or related entities in the provided information.

7. Privateering — Unclear. While Omni Medsci Inc. is asserting the patent, and the transfers appear to be internal to the inventor's controlled entities, there is no explicit information detailing whether an operating company transferred the patent to Omni Medsci Inc. to assert on its behalf against competitors.

8. Defensive aggregator (anti-NPE) — Not present. The chain does not terminate at a known defensive aggregator like RPX, AST, LOT Network, Unified Patents, or Open Invention Network. Instead, the patent is being actively asserted.

Verdict

NPE — high confidence

The assignment history of US9055868 exhibits multiple strong signals indicative of an NPE. Specifically, the cascading transfers between Omni Medsci Inc., Omni Continuum LLC, and Cheetah Omni LLC (Reel 059952/1000 and 061614/0001), all entities with unclear product lines related to the patent and a focus on patent acquisition/transfer (Reel 061614/0001), point to shell-entity transfers. The consistent use of the same correspondent, Robert R. Deleault, for multiple transfers reinforces the pattern of a coordinated patent monetization strategy. Furthermore, the initiation of infringement litigation by Omni Medsci Inc. in January 2025, following these transfers, confirms an assertion-focused approach.

USPTO Assignment Center search page for US9055868: https://assignmentcenter.uspto.gov/patent/index.html - search by patent number 9055868